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ABSTRACT: Methionyl-tRNA synthetase (MetRS) has been
chemically validated as a drug target in the kinetoplastid
parasite Trypanosoma brucei. In the present study, we
investigate the validity of this target in the related
trypanosomatid Leishmania donovani. Following development
of a robust high-throughput compatible biochemical assay, a
compound screen identiﬁed DDD806905 as a highly potent
inhibitor of LdMetRS (Ki of 18 nM). Crystallography revealed
this compound binds to the methionine pocket of MetRS with
enzymatic studies conﬁrming DDD806905 displays compet-
itive inhibition with respect to methionine and mixed
inhibition with respect to ATP binding. DDD806905 showed
activity, albeit with diﬀerent levels of potency, in various Leishmania cell-based viability assays, with on-target activity observed in
both Leishmania promastigote cell assays and a Leishmania tarentolae in vitro translation assay. Unfortunately, this compound
failed to show eﬃcacy in an animal model of leishmaniasis. We investigated the potential causes for the discrepancies in activity
observed in diﬀerent Leishmania cell assays and the lack of eﬃcacy in the animal model and found that high protein binding as
well as sequestration of this dibasic compound into acidic compartments may play a role. Despite medicinal chemistry eﬀorts to
address the dibasic nature of DDD806905 and analogues, no progress could be achieved with the current chemical series.
Although DDD806905 is not a developable antileishmanial compound, MetRS remains an attractive antileishmanial drug target.
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Kinetoplastid parasites of the Leishmania species areresponsible for leishmaniasis, a neglected tropical disease
prevalent in 98 countries, with 350 million people at risk.1
These protozoan parasites are transmitted by the bite of
phlebotomine sandﬂies leading to the development of visceral,
cutaneous, or mucocutaneous leishmaniasis; the former of
which is fatal if untreated.1 As with most neglected diseases, the
treatment options currently available suﬀer from limitations,
including high cost, host toxicity, emerging drug resistance, and
suboptimal dosing regimens, leading to a pressing need to
discover new therapeutics.2,3
In the search for new antileishmanial therapeutics, we have
adopted a balanced approach to drug discovery, with both
phenotypic screening campaigns and target-based approaches
providing the best opportunity to discover a range of new
chemical matter.4,5 A particular challenge associated with target-
based approaches is a lack of fully validated drug targets in
Leishmania.1 Targets are therefore selected on the basis of those
involved in highly essential biological pathways and extrap-
olation of validation data from related trypanosomatid parasites.
Methionyl-tRNA synthetase (MetRS; EC 6.1.1.10) meets both
criteria as this enzyme plays a crucial role in protein synthesis,6
a fundamental pathway in all organisms, and has also been
validated as a druggable target in the closely related
Trypanosoma brucei parasite, with inhibitors of T. brucei
MetRS shown to cure T. brucei bloodstream infections in a
mouse model of human African trypanosomiasis.7−10 As a
family, tRNA synthetases have also been shown to be good
targets in the anti-infectives space.11−13 MetRS was therefore
prioritized as a target for entry into a Leishmania drug discovery
program.
MetRS catalyzes the synthesis of methionyl-tRNA in a two-
step reaction; the ﬁrst step results in the production of a
methionyl-AMP intermediate and pyrophosphate, with the
second step resulting in the production of methionyl-tRNA and
AMP.14 This enzyme is highly conserved among kinetoplastid
parasites (both T. brucei and Trypanosoma cruzi MetRS are 76%
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similar to the Leishmania enzyme at the amino acid level). A
key challenge in therapeutically targeting a well conserved
enzyme is achieving selectivity over the homologous human
protein. As Leishmania MetRS is more closely related to the
human mitochondrial MetRS (81% sequence identity in
catalytic pocket) compared to the human cytoplasmic enzyme
(41% identity in catalytic pocket), assessing selectivity over the
human mitochondrial form, as well as human protein synthesis,
will be important in a drug discovery program.
In the present study, the validity of MetRS as a target in
Leishmania donovani was investigated. Extrapolation of data
from T. brucei suggests the L. donovani enzyme will also be an
essential and druggable target, with development of a
biochemical, high-throughput compatible screening assay
possible.7,8,15,16 In addition, the availability of several down-
stream tools provides an eﬀective route for characterizing and
progressing any MetRS inhibitors identiﬁed. These include
T. brucei and Leishmania major MetRS crystal structures17,18
which provide powerful tools for cocrystallizing any inhibitors
identiﬁed, thus providing insight into the binding mode with
the target. In addition, several phenotypic cell-based screens are
available and are routinely used as part of the Leishmania drug
discovery pipeline.19 Such assays include the use of free-living
promastigote or axenic amastigote parasites (from the insect
stage and mammalian stage of the Leishmania life cycle,
respectively) and the more complex, but more physiologically
relevant, intracellular amastigote assay.20−24 Furthermore, an in
vivo model of leishmaniasis allows progression of molecules
through to a recognized animal model of this neglected
disease.25
Here, we describe the identiﬁcation of L. donovani MetRS
(LdMetRS) inhibitors, characterize the binding mode of our
lead molecule using crystallographic and biochemical methods,
and conﬁrm on-target activity in cells. Unfortunately, our lead
molecule did not show eﬃcacy in our leishmaniasis animal
model; we include discussions around potential explanations
for this failure to translate.
■ RESULTS AND DISCUSSION
Identiﬁcation of the LdMetRS Inhibitor DDD806905.
Recombinant LdMetRS was produced, and a biochemical
enzyme assay, using the BIOMOL Green assay platform, was
developed to monitor the ﬁrst step of the MetRS reaction,
namely, the reaction of methionine and ATP to produce
methionyl-AMP and pyrophosphate. Assay conditions were
reﬁned to ensure optimal screening conditions were employed.
This involved assessing buﬀer conditions and determining the
optimal enzyme concentration, assay linearity with respect to
time, and Michaelis constants for methionine and ATP (Figure
1A−D). The apparent Km for methionine was determined to be
173 ± 83 μM (with a Hill slope of 0.57 ± 0.06) and 37 ± 3 μM
for ATP (with ATP also displaying substrate inhibition with an
apparent Ki of 482 ± 44 μM)). The Hill slope of 0.57 observed
with methionine can be indicative of negative cooperativity
between two subunits of a dimeric protein as observed for
MetRS from Bacillus stearothermophilus.26 However, analysis of
the oligomeric state of the protein using SEC-MALS (size
exclusion chromatography−multi-angle light scattering) sug-
gests the protein is monomeric (Figure S1), supporting
previously published crystallography data showing that the
Figure 1. LdMetRS assay development summary. (A) Linearity of the assay with respect to enzyme concentration. (B) Methionine Km
determination in the presence of a saturating concentration of ATP (200 μM). Solid line is best ﬁt to Hill equation and dotted line to Michaelis−
Menten equation. (C) ATP Km determination in the presence of a saturating concentration of methionine (1 mM). (D) Assay linearity with respect
to time under the ﬁnal assay screening conditions of 50 μM methionine and 100 μM ATP either with (closed circles) or without (open circles) 50
nM LdMetRS enzyme. Data are shown as mean ± SD (n = 3 technical replicates).
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L. major crystal structure is monomeric.18 An alternative
explanation for the low Hill slope could be conformational
selection as previously observed for inhibitors binding to the
T. brucei MetRS enzyme.27 In this model, two conformations of
the ligand-free enzyme exist, with diﬀering aﬃnities for ligands
and diﬀerent kcat values.
28
Using ﬁnal assay conditions of 50 nM LdMetRS, 50 μM
methionine, and 100 μM ATP, a panel of compounds closely
related to known inhibitors of bacterial MetRS29 (24 members
of a 2-amino benzimidazole series, along with a singleton 2-
aminoquinazolin-4-one) was screened. These compounds
inhibited the LdMetRS enzyme with a range of potencies
(IC50 values of 94 nM to 100 μM) (Table S1), the most active
compound being the 2-aminoquinazolin-4-one singleton
DDD806905 (IC50 of 94 nM (95% CI, 57−156 nM)) (Figure
2A).
The IC50 value for DDD806905 determined in this screening
assay was close to the enzyme concentration used in the
reaction, meaning DDD806905 was potentially displaying tight
binding inhibition under the assay conditions employed. To
more accurately deﬁne the potency of DDD806905, it is more
appropriate to ﬁt the dose response data to the Morrison
equation30 (eq 3 in the Supporting Information). Prior to
ﬁtting data to the Morrison equation, an accurate determination
of the active enzyme concentration is required. This was
achieved by titrating the LdMetRS enzyme in the presence of 1
μM DDD806905 (Figure S2A), revealing that 78% of the
LdMetRS protein sample is catalytically active. This resulted in
an LdMetRS active enzyme concentration of 39 nM. Using this
value as a constant and ﬁtting dose response data to the
Morrison equation revealed a DDD806905 Ki
app of 41 nM
(Figure S2B).
Characterization of DDD806905 Binding and Mode of
Inhibition. Determination of the binding mode of the
aminoquinazolinone inhibitor DDD806905 was carried out
using both crystallographic and biochemical methods. For
crystallographic determination of the binding mode, T. brucei
MetRS (TbMetRS) protein was used as a structural surrogate
(Table S2). Despite an overall sequence identity of only 76%
between LdMetRS and the TbMetRS, the residues lining and
surrounding the ligand binding site are highly conserved
(Figure S3) with a sequence identity of 95%. The only
sequence diﬀerence within the site is a conservative valine to
leucine substitution (TbMetRS Leu 456); therefore, TbMetRS
is a valid structural system to understand the mode of action for
DDD806905 against LdMetRS.
Previous studies have shown that the binding of amino-
quinolone inhibitors stabilize an open conformation of
TbMetRS with expansion of the methionine binding pocket
and opening of an auxiliary binding pocket.17 The
TbMetRS:DDD806905 complex shows the ligand to bridge
the auxiliary pocket (AP) and expanded methionine pocket
(EMP) of the enzyme (Figure 2B). Overlaying the binding
mode of DDD806905 with the intermediate methionyl
adenylate (PDB 4EG3)27 shows the linker between the
dichloro indole and quinazolinone groups would block the
binding of the beta phosphate group of ATP. The ligand
stabilized opening of the AP involves a change in rotomer of
Figure 2. DDD806905 binding mode. (A) DDD806905 was identiﬁed as our lead LdMetRS inhibitor, with an IC50 of 94 nM. (B) Crystal structure
of TbMetRS:DDD806905 (PDB 5NFH). DDD806905 bridges the expanded methionine pocket (EMP) and the ligand stabilized auxiliary pocket
(AP). The dichloroindole moiety occupies the same site as methionine (C atoms gray). The solvent accessible surface of TbMetRS:DDD806905 is
shown in dark green. (C) Comparison of the binding mode of DDD806905 (C atoms gold) compared to TbMetRS:methionyl adenylate (MAMP, C
atoms gray, PDB 4EG3). (D) Binding mode of TbMetRS:DDD806905 showing protein side chains that line the binding site. (E) H-bond
interactions between quinazolinone moiety of DDD806905 and residues lining the auxiliary pocket. H-bond interactions are shown as dashed lines
and water molecules as red spheres, and key residues are labeled. (F) The binding modes of DDD806905 (C atoms gold) compared with
aminoquinolone ligand Chem 1312 PDB 4EG5 (C atoms green). (G) Sequence conservation is high between TbMetRS and LdMetRS around the
DDD806905 binding site with identical residues colored red and nonidentical colored gray.
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Tyr250, a consequence of which is the widening of the ATP
binding cleft which may reduce the aﬃnity for ATP (Figure
2C). The side chains lining the DDD806905 binding site are
largely hydrophobic in nature (Figure 2D) with limited polar
interactions. The quinazolinone moiety occupies the AP pocket
retaining key bidentate H-bonds between the quinazolinone
NH and the amino NH of Asp287 (Figure 2E). The carbonyl
moiety forms an H-bond to a water molecule coordinated by
the side chain of Tyr250 and the backbone NH of Lys292. The
4,6-dichloro indole moiety occupies the EMP pocket with the
6-chloro atom overlaying with the substrate methionine S atom
(Figure 2C). The indole NH does not make any speciﬁc
interactions with protein. The binding mode of DDD806905 is
similar to the published aminoquinolone complex (PDB 4EG5)
(Figure 2F) with a root-mean-square deviation of 0.22 Å for the
position of all residues within 5 Å of the ligand between
Figure 3. DDD806905 mode of inhibition. (A) LdMetRS biochemical mode of inhibition studies were carried out with reciprocal plots of A650 and
substrate concentration revealing that DDD806905 displays competitive inhibition with respect to methionine with a Ki of 18 nM calculated. (B)
Mode of inhibition studies also revealed that DDD806905 displays mixed inhibition with respect to ATP with a Ki of 21 nM calculated. Inhibitor
concentrations used were as follows: 2 × IC50 (closed circles), 1 × IC50 (open circles), 0.5 × IC50 (closed triangles), and 0 × IC50 (open triangles).
Figure 4. DDD806905 inhibits Leishmania in vitro translation. (A) In vitro translation in a Leishmania tarentolae extract was monitored over time by
tracking expression of an eGFP construct (closed circles), with a “minus construct” negative control included (open circles). (B) The ability of
DDD806905 to inhibit expression of eGFP in the L. tarentolae extract was investigated with this LdMetRS inhibitor inhibiting protein synthesis with
an EC50 of 2.2 μM (closed circles). In the presence of an additional 1.5 mM methionine, the EC50 was shifted to 12 μM (open circles), indicative of
on-target activity, as DDD806905 is a known methionine competitive inhibitor of LdMetRS. (C) In vitro translation in a HeLa cell extract was also
monitored by tracking expression of a GFP construct (closed circles) over time, with “minus construct” (closed triangles) and cycloheximide
(protein synthesis inhibitor) controls (open circles) included. When DDD806905 was included at a concentration of 100 μM (open triangles), no
inhibition of in vitro translation was observed in this human cell extract. Data are shown as mean ± SD (n = 3 technical replicates (cycloheximide
data, n = 2 technical replicates)).
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TbMetRS:DDD806905 and the aminoquinolone complex
4EG5. The residues that form the ligand binding site and
those that facilitate the conformational change in the CP
domain are highly conserved between TbMetRS and LdMetRS
(Figures 2G and S3), conﬁrming that TbMetRS is a valid model
system to understand the binding mode of DDD806905.
Further characterization of the mode of inhibition of
DDD806905 was carried out biochemically by varying each
substrate concentration at various inhibitor concentrations.
Each data set was individually ﬁtted to the Michaelis−Menten
equation or a modiﬁed high-substrate inhibition Michaelis−
Menten equation, and the resulting Lineweaver−Burk plots
were examined for diagnostic patterns of competitive, mixed, or
uncompetitive inhibition.
Data from these analyses indicate that DDD806905 displays
competitive inhibition with respect to methionine binding
(Figure 3A), and further ﬁtting to a global competitive
inhibition model (eq 4 in the Supporting Information) resulted
in a DDD806905 Ki of 18 ± 2 nM (Ki ± SE) being returned.
This biochemically determined methionine competitive behav-
ior conﬁrmed the crystallographic data which revealed
DDD806905 binds to the methionine pocket of MetRS.
This DDD806905 mode of inhibition study was repeated
using ATP as the variable substrate. Fitting these data sets to
the modiﬁed high-substrate inhibition Michaelis−Menten
equation and plotting a double-reciprocal plot of the data
revealed the characteristic substrate inhibition proﬁle shown in
Figure 3B (solid lines). To allow global ﬁtting, we excluded the
substrate concentrations at which substrate inhibition was
observed. The remaining data were ﬁtted to a mixed inhibition
model (eq 5 in Supporting Information). It can be seen that
DDD806905 displays characteristic mixed inhibition with
respect to ATP binding (Figure 3B, dashed lines). This ATP
mode of inhibition study returned a DDD806905 Ki of 21 ± 5
nM (Ki ± SE), which is highly comparable to the Ki calculated
from the methionine competitive inhibition experiment
previously described.
From the ATP study, it should also be noted that the Ki′
value of 227 ± 23 nM indicates DDD806905 binds
preferentially to the free enzyme and the inhibitor proﬁle is
more closely related to competitive inhibition. This supports
kinetic data which reveals there is positive cooperativity
between the methionine and ATP pockets (methionine Km
shifts from 170 to 1500 μM when either 400 μM ATP (10 ×
Km) or 80 μM ATP (2 × Km) is used, respectively (Figure S4)),
a feature also observed in MetRS from E. coli, B. stearothermo-
philus, and S. aureus.31−33 Consequently, alterations in ATP
concentration can impact both binding of methionine and
DDD806905 in the methionine pocket. This interaction
between ATP and methionine sites is further conﬁrmed from
inhibitor studies using diﬀerent substrate concentrations. These
show that the IC50 of DDD806905 increases when either
methionine or ATP concentrations are increased suggesting
that both substrates have “competitive like” proﬁles (Figure
S5A−C).
DDD806905 Inhibits in Vitro Translation. Inhibitors of
the LdMetRS enzyme would be expected to inhibit protein
synthesis. To conﬁrm whether this was the case, DDD806905
was tested for its ability to inhibit protein synthesis in a
commercially available Leishmania tarentolae cell extract.34−36
Initial experiments revealed that production of an eGFP protein
from a plasmid containing the eGFP gene can be monitored in
this system using a 384-well assay format and a standard plate-
based reader (Figure 4A).
Subsequently, the ability of DDD806905 to inhibit
production of this eGFP protein was determined, with
DDD806905 shown to inhibit protein synthesis with an EC50
of 2.2 μM (Figure 4B, closed circles). This potency is
considerably weaker than that observed in the biochemical
enzyme assay, where DDD806905 returned an IC50 of 94 nM.
One possible reason for this 23-fold drop oﬀ in potency is the
diﬀerence in substrate concentrations present in the respective
assays (the biochemical assay was run using methionine and
ATP concentrations of 50 and 100 μM, respectively, whereas
the L. tarentolae cell extracts were supplemented with 136 μM
methionine and 1200 μM ATP in addition to their endogenous
concentrations). As described above, the potency of
DDD806905 is seen to shift in the biochemical assay when
substrate concentrations are increased, accounting, at least in
part, for the diﬀerent potencies observed in the biochemical
assay and L. tarentolae cell extract.
To demonstrate that inhibition of translation in the
L. tarentolae cell extract was indeed through inhibition of
MetRS, the potency of DDD806905 in the protein synthesis
assay was determined in the presence and absence of an
additional 1.5 mM methionine. When extra methionine is
present in the assay, there is a 5-fold shift in DDD806905
potency (EC50 shift from 2.2 to 12 μM), highly indicative of on-
target activity against MetRS (Figure 4B).
It was interesting to note that, when DDD806905 was tested
in a similar in vitro translation assay using a human HeLa cell
extract, no inhibition of protein synthesis was observed (Figure
4C). Although this observation does not prove selectivity over
the more closely related human mitochondrial MetRS enzyme,
it does indicate that DDD806905 fails to inhibit the human
cytoplasmic MetRS enzyme when tested at a concentration of
100 μM. To investigate potential mitochondrial toxicity, we
carried out a mitochondrial protein synthesis assay which
revealed some inhibition of mitochondrial protein synthesis
with an IC50 of 1.7 μM (95% CI, 1.0−2.8 μM) (Figure S6). In
addition, DDD806905 showed toxicity against Leishmania
infected, PMA-diﬀerentiated THP-1 cells (THP-1 EC50, 10
μM). Reducing mammalian cell toxicity and the level of
mitochondrial protein synthesis inhibition would therefore have
to be an important goal of a drug development program.
Cellular and in Vivo Eﬃcacy of DDD806905. To
investigate whether DDD806905 has antileishmanial activity,
it was tested in a L. donovani intracellular amastigote assay,
where an EC50 of 2.9 μM (95% CI, 2.2−3.8 μM; n = 8) was
determined (Figure S7). Next, we progressed DDD806905 to
an in vivo mouse visceral leishmaniasis eﬃcacy model.
Unfortunately, no eﬃcacy was observed (Figure 5), with only
a 19% knock-down of liver parasite counts observed after 50
mg/kg, twice daily oral dosing for 10 days, compared to vehicle
dosed control animals. In contrast, the clinically used control
compound miltefosine displayed 99.6% parasite knock-down
following 30 mg/kg, once daily oral dosing for 10 days. Blood
levels of DDD806905 were measured during the eﬃcacy study
and showed that drug total levels were maintained above the
MIC (minimum inhibitory concentration = 4.3 μM) measured
in the intracellular assay for at least 8 h after dosing (Figure
S8A,B). However, due to very high plasma protein binding (fu
= 0.006 in mouse plasma and 0.007 in human plasma), blood
free levels of DDD806905 were signiﬁcantly below the in vitro
MIC. To gain insight into the importance of protein binding,
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we performed an in vitro serum shift assay with DDD806905
against Leishmania promastigotes which revealed the expected
linear correlation between promastigote EC50 and amount of
protein in the media (Figure S9).37 Since in vivo eﬃcacy is
usually also driven by the drug free level, the very high plasma
protein binding is likely a key reason for the lack of activity for
DDD806905 in our visceral leishmaniasis model. Interestingly,
a related MetRS inhibitor was also shown not to be curative in
an animal model of human African sleeping sickness in spite of
having promising in vitro cell activity.7
Eﬃcacy of MetRS Inhibition in Promastigotes and
Axenic Amastigotes and On-Target Activity. The above
experiments showed that DDD806905 was around 10-fold
more potent against Leishmania promastigotes compared to
intracellular amastigotes (EC50‑pro of 0.27 μM (95% CI, 0.25−
0.29 μM) (in 10% serum), EC50‑intracellular of 2.9 μM (95% CI,
2.2−3.8 μM)). The compound was also found to be 50-fold
less active against axenic amastigotes relative to promastigotes
(EC50‑axam of 13.7 μM (95% CI, 10.5−17.6 μM)). To assess on-
target activity and further explore potential life-cycle stage
diﬀerences in susceptibility, a series of related 2-amino
benzimidazoles with varying degrees of LdMetRS potency
were tested for their ability to inhibit Leishmania parasite
growth, using both promastigote and axenic amastigote
Leishmania viability assays (Table S1). As for DDD806905,
the compounds in this panel showed a large drop in potency
from promastigotes to amastigotes. A reasonable correlation is
Figure 5. DDD806905 mouse visceral leishmaniasis eﬃcacy study with
integrated pharmacokinetics. Eﬃcacy of DDD806905 was assessed in a
mouse model of visceral leishmaniasis at 50 mg/kg b.i.d. for 10 days,
along with vehicle (b.i.d. for 10 days) and miltefosine (30 mg/kg q.d.
for 10 days) controls. Mean reduction in liver parasite burden
expressed as Leishman Donovan Units (LDU). Miltefosine revealed a
99.6% reduction in liver LDU compared to vehicle control (***p <
0.001), with DDD806905 showing only a 19.4% reduction in liver
LDU (integrated pharmacokinetics results shown in Figure S8).
Figure 6. Cellular eﬃcacy of LdMetRS inhibition. (A) A panel of LdMetRS inhibitors show a range of potencies (IC50 94 nM to 100 μM) in the
LdMetRS enzymatic assay. Plotting the −log IC50 (pIC50) of this enzymatic data against −log EC50 (pEC50) data from the L. donovani promastigote
assay reveals these potencies correlate well. Solid line represents linear regression with a correlation coeﬃcient of 0.76. (B) When the same
compounds are tested in the L. donovani axenic amastigote assay, most are inactive. In both (A) and (B), dashed lines represent equipotency in the
LdMetRS enzyme assay and the Leishmania phenotypic assay. (C) Conﬁrmation of on-target activity of DDD806905 in L. donovani promastigotes
was carried out by testing this compound in the absence (closed circles) and presence (open circles) of excess methionine (2 mM). The EC50 shifts
from 0.46 to 1.9 μM in the absence and presence of excess methionine, respectively. Data presented as mean ± SD (n = 3 biological replicates).
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observed between enzyme data and L. donovani promastigote
data (Figure 6A), suggestive of on-target activity, whereas these
same compounds showed low, or no, inhibition in the
L. donovani axenic amastigote assay (Figure 6B).
While the correlation between enzyme data and promasti-
gote data is indicative of on-target activity, further studies
attempted to conﬁrm whether this was the case. Initial eﬀorts to
conﬁrm the on-target eﬀect of DDD806905 were explored by
attempting to generate MetRS overexpressing and knockout
Leishmania cell lines. All eﬀorts to modulate MetRS expression
levels in L. donovani proved to be toxic to the parasite,
suggesting that tight regulation of this enzyme is important to
parasite survival, supporting the validation of MetRS as a highly
essential target in Leishmania.
In the absence of MetRS overexpressing or knockout cell
lines, alternative methods were used to determine on-target
inhibition of MetRS in the parasite. As with the in vitro
translation system, DDD806905 was tested in a Leishmania
promastigote assay in both the presence and absence of extra
methionine. The EC50 of this compound shifted from 0.46 to
1.9 μM after addition of extra methionine, highly indicative of
on-target activity (Figure 6C).
Properties of DDD806905 Accounting for Potency
Diﬀerences between Life-Cycle Stages. To account for the
discrepancy in data from the diﬀerent Leishmania parasite
assays, it is noteworthy that these cell assays were performed in
media at diﬀerent pH values (with promastigote and axenic
amastigote assays run in media at pH 7.3 and pH 5.6,
respectively) and that in the intracellular amastigote assay the
parasites reside inside the acidic parasitophorous vacuole. We
experimentally determined the pKa’s for DDD806905 (Figure
S10A) (pKa of 3.4, 7.5 and 11), and the data shows that, at pH
7.3, 0.01% of the compound is present in an un-ionized state.
This falls to essentially 0% at pH 5.6. In addition, the
lipophilicity of the compound was signiﬁcantly reduced at pH
5.6 (measured log D5.6 of 0.3) compared with the lipophilicity
at pH 7.3 (measured log D7.3 of 2.6) (Figure S10B). The lower
total level of uncharged, membrane permeable, compound in
acidic axenic amastigote media compared to neutral promas-
tigote media will result in a lower intracellular compound
Table 1. Enzyme Inhibition and Cellular Data for DDD806905 and Analogues
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concentration, providing a potential explanation for the reduced
potency in this assay. In the intracellular assay, the parasites also
reside in an acidic compartment, but the total acidic volume is
much smaller in this setting (volume of acidic organelles only
versus volume of media and acidic organelles in the axenic
assay), resulting in a higher fraction of uncharged, membrane
permeable compound under intracellular conditions.
Attempts were made to increase the fraction of nonionized
species by chemically modifying DDD806905 to reduce its
basicity. Unfortunately, all attempts to test this hypothesis by
modifying the benzylic amine resulted in signiﬁcant loss of
activity against the enzyme (Table 1). In particular, converting
the pendant amine to the corresponding amide, i.e.,
DDD806905 cf. compound 25 (also compound 26 cf.
compound 27) or sulphonamide, i.e., compound 26 cf.
compound 28 reduced enzyme activity. Similarly, removal of
the basic nitrogen by replacement with methylene, i.e.,
compound 29 cf. compound 26, removed enzyme activity. In
addition, substitution of the 2-nitrogen for an oxygen (i.e.,
DDD806905 cf. compound 31) was not tolerated. Methylating
the benzylic amine (compound 30), which is not expected to
change basicity, was tolerated, but it did not improve cellular
activity.
Therefore, despite medicinal chemistry eﬀorts to reduce the
basicity of DDD806905, the SAR suggests that the basic
nitrogen is required for activity and DDD806905 remains our
lead LdMetRS inhibitor. These results support the hypothesis
that the lack of activity seen in the axenic amastigote assay is
not due to MetRS being a poor drug target but rather due to
poor drug partitioning into axenic amastigotes resulting from
the highly protonated state of the active compounds in acidic
media.
DDD806905 is Lysosomotropic. Due to its highly
protonated state under acidic conditions, it is conceivable
that DDD806905 is accumulating in acidic cellular compart-
ments, which could help explain the lower potency in the
intracellular assay relative to the promastigote assay and may
contribute to the lack of activity in the animal eﬃcacy study. To
assess this, we carried out a lysosomal sequestration assay.38,39
The results in Figure 7 reveal that DDD806905 indeed shows
the hallmarks of lysosomal accumulation/trapping, whereas, as
expected, the nonbasic sulphonamide analogue compound 28
does not. We also conﬁrmed the well-known lysosomal
accumulation of the antimalarial drug chloroquine.40 For
chloroquine, this is essential as its mode of action depends
on accumulation in the acidic food vacuoles of the malaria
parasite. In our intracellular Leishmania assay, the host cells
present a relatively large lysosomal compartment,41,42 and on
the basis of the data presented here, we propose that the THP-
1 lysosomes act as a sink for DDD806905, thus reducing the
amount of free, membrane permeable compound available to
reach the parasites, hence contributing to the potency drop-oﬀ
seen between promastigotes and intracellular amastigotes. We
also measured the volume of distribution (Vdss) for
DDD806905 in mice following a single intravenous dose and
found it to be high (6 L/kg), indicating accumulation of the
compound in tissues, which is in line with the lysosomotropism
observed in vitro.
■ CONCLUSIONS
We have successfully set up an assay for LdMetRS and
established that analogues of bacterial and T. brucei MetRS
inhibitors inhibit the Leishmania enzyme. These compounds
almost certainly bind in a very similar manner to the Leishmania
enzyme as they do to the T. brucei enzyme. We have also
demonstrated that these compounds are active against
L. donovani promastigotes. Taken together, the correlation
between enzyme activity and promastigote activity (Figure 6A),
on-target activity in an in vitro protein translation assay (Figure
4B), the cocrystal structure of DDD806905 with MetRS, and
the competition experiment with methionine (Figure 6C)
provide compelling evidence that the compounds are working
on target in promastigotes. However, the compounds showed
lower activity against the intramacrophage form of the parasite
and no in vivo eﬃcacy. On the basis of the results presented
here, the most likely reason for the lack of in vivo eﬃcacy of
DDD806905 is its very small free and membrane permeable
fraction due to a combination of high protein binding,
ionization, and accumulation in acidic compartments. Although
this compound has failed to translate into in vivo eﬃcacy, this
does not invalidate MetRS as a potential drug target in
Leishmania. Indeed, MetRS remains an attractive drug target in
this parasite, and further eﬀorts to identify novel starting
chemical matter against this enzyme target are underway.
■ MATERIALS AND METHODS
Materials and methods can be found in the Supporting
Information. These include experimental procedures for
LdMetRS and TbMetRS expression and puriﬁcation; LdMetRS
biochemical assays; TbMetRS crystallography; Leishmania and
human in vitro translation assays; in vitro Leishmania assays;
mouse eﬃcacy study and integrated PK; in vitro physicochem-
ical measurements; chemical synthesis of compounds.
All human biological samples were sourced ethically, and
their research use was in accord with the terms of the informed
consents. All animal studies were ethically reviewed and carried
out in accordance with Animals (Scientiﬁc Procedures) Act
1986 and the GSK Policy on the Care, Welfare and Treatment
of Animals.
Figure 7. DDD806905 accumulates in acidic compartments. Ability of
compounds to compete with lysotracker red accumulation in THP-1
lysosomes was assessed and revealed that both DDD806905 (open
circles) and a positive control compound chloroquine (closed circles)
did compete with lysotracker red accumulation in this acidic
compartment. Representative data shown (mean ± SD, n = 3
biological replicates). In contrast to DDD806905 and chloroquine,
compound 28 (open triangles) does not compete with lysotracker red
for accumulation in THP-1 lysosomes. Representative data shown
(mean ± SD, n = 2 biological replicates).
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